| Trial ID: | L0764 |
| Source ID: | NCT03864783
|
| Associated Drug: |
Curcumin
|
| Title: |
The Effect of Curcumin on Liver Fat Content in Obese Subjects
|
| Acronym: |
--
|
| Status: |
Not recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Non-Alcoholic Fatty Liver Disease;Insulin Resistance;Glucose Tolerance Impaired;Obesity, Abdominal
|
| Interventions: |
Dietary Supplement: Curcumin (Meriva??);Drug: Placebo Oral Tablet
|
| Outcome Measures: |
Curcumin's effect on steatosisCurcumin's effect on concentration of total amino acids in plasma;Curcumin's effect on plasma concentration of urea;Curcumin's effect on urin concentration of urea;Curcumin's effect on serum concentration of inflammatory marker interleukin (IL)-1b;Curcumin's effect on serum concentration of inflammatory marker IL-2;Curcumin's effect on serum concentration of inflammatory marker IL-6;Curcumin's effect on serum concentration of inflammatory marker IL-10;Curcumin's effect on serumconcentration of inflammatory marker tumor necrosis factor (TNF)-alpha;Curcumin's effect on plasma concentration of adipokines;Curcumin's effect on plasma concentration of glucagon;Curcumin's effect on plasma concentration of glucagon-like peptide 1;Curcumin's effect on plasma concentration of glucose-dependent insulinotropic peptide;Curcumin's effect on glucose plasma values during an oral glucose tolerance test for 4 hours;Curcumin's effect on serum c-peptide levels;Curcumin's effect on serum insulin concentration;Curcumin's effect on serum concentration of free fatty acids;Curcumin's effect on liver insulin resistance;Curcumin's effect on body weight in kilograms;Curcumin's effect on BMI (kg/m^2);Curcumin's effect on waist circumference (cm);Curcumin's effect on waist-hip ratio;Curcumin's effect on systolic blood pressure (mmHg);Curcumin's effect on diastolic blood pressure (mmHg);Curcumin's effect on transient elastography liver stiffness measurements (kPa);Curcumin's effect on transient elastography controlled attenuation parameter (CAP) value (dB/m);Curcumin's effect on gut microbiota (relative abundance);Curcumin's effect on gut microbiota (alpha/beta diversity);Curcumin's effect on gut microbiota (link to phenotype of interest);Curcumin's effect on visceral fat (cm);Curcumin's effect on subcutaneous fat (cm);Curcumin's effect on muscle percentage;Curcumin's effect on fatt mass;Curcumin's effect on fat percentage;Curcumin's effect on fat-free mass;Curcumin's effect on fat-free mass percentage;Curcumin's effect on total body water;Curcumin's effect on body water percentage;Curcumin's effect on prospective food consumption;Curcumin's effect on food consumption;Curcumin's effect on calory balance;Curcumin's effect on plasma concentration of cholesterol;Curcumin's effect on plasma concentration of alanine aminotransferase;Curcumin's effect on plasma concentration of aspartate aminotransferase;Genetic risk markers for development of NASH
|
| Sponsor/Collaborators: |
Steno Diabetes Center Copenhagen
|
| Gender: |
Male
|
| Age: |
20 Yearsnan
|
| Phases: |
Not applicable
|
| Enrollment: |
39
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
|
| Start Date: |
26/02/2019
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
16 February 2021
|
| Locations: |
Denmark
|
| URL: |
https://clinicaltrials.gov/show/NCT03864783
|
